Malignant neoplasms of the organs of the reproductive system have the largest share in the structure of oncological morbidity in women - 37.3%, and genital tumors account for 17.3% of all malignant neoplasms. According to the International Agency for Research on Cancer (IARC), about 500,000 new cases of malignant neoplasms of the cervix, almost 320,000 cases of endometrial cancer and 240,000 cases of ovarian cancer are registered annually in the world. In our research r=the studied patients were divided into two groups. The main group consisted of 52 patients with IB2, IIB and IIIB stages of CEM who underwent neoadjuvant chemotherapy followed by radical surgery and/or chemoradiotherapy. Determination of the risk of adverse prognostic factors with careful dynamic monitoring of the tumor process is one of the main conditions for the use of multicomponent treatment of patients with REM. The technological basis of monitoring is the integration of MRI and ultrasound into diagnostic standards.

Malignant neoplasms, endometrial cancer, neoadjuvant chemotherapy

Alcazar, J.L. Three-Dimensional Power Doppler Ultrasound for Predicting Response and Local Recurrence After Concomitant Chemoradiation Therapy for Locally Advanced Carcinoma of the Cervix / J.L. Alcazar, S. Arribas, R. MartinezMonge et al. // Int. J. Gynecol. Cancer. ‒ 2016. ‒ Vol. 26, N 3. ‒ P. 534-538.

Amin, M.B. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging / M.B. Amin, F.L. Greene, S.B. Edge et al. // CA Cancer J. Clin. ‒ 2017. ‒ Vol. 67, N 2. ‒ P. 93-99.

Guyot, M. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies / M. Guyot, C. Hilmi, D. Ambrosetti // Oncotarget. ‒ 2017. ‒ Vol. 8, N 6. ‒ P. 9174-9188.

Colombo, N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / N. Colombo, S. Carinelli, A. Colombo et al. // Ann. Oncol. ‒ 2012. ‒ Vol. 23 Suppl. 7. ‒ P. vii27-32.

D'Agostino, G. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin / G. D'Agostino, M. Distefano, S. Greggi et al. // Cancer Chemother. Pharmacol. ‒ 2002. ‒ Vol. 49, N 3. ‒ P. 256-260.

Hu, K. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy / K. Hu, W. Wang, X. Liu et al. // Radiat. Oncol. ‒ 2018. ‒ Vol. 13, N 1. ‒ P. 249.

Huguet, F. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion / F. Huguet, O.M. Cojocariu, P. Levy et al. // Int. J. Radiat. Oncol. Biol. Phys. ‒ 2008. ‒ Vol. 72, N 5. ‒ P. 1508-1515.

Jennings, T.S. Results of selective use of operative laparoscopy in gynecologic oncology / T.S. Jennings, P. Dottino, J. Rahaman et al. // Gynecol. Oncol. ‒ 1998. ‒ Vol. 70, N 3. ‒ P. 323-328.

Koh, W.J. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology / W.J. Koh, N.R. Abu-Rustum, S. Bean et al. // J. Natl. Compr. Canc. Netw. ‒ 2019. ‒ Vol. 17, N 1. ‒ P. 64-84.

Kubik, S. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse / S. Kubik, M. MoszynskaZielinska, J. Fijuth et al. // Prz. Menopauzalny. ‒ 2019. ‒ Vol. 18, № 1. ‒ P. 23-26.